人民财讯1月26日电，中农联合（003042）1月26日发布2025年度业绩预告，公司预计2025年度归属于上 市公司股东的净利润亏损1.28亿元—1.65亿元，上年同期亏损1.22亿元。报告期内，受公司主要产品市 场价格持续低位下行影响，公司主营业务毛利率偏低，同时，新建成项目试运行期间成本较高，导致公 司报告期内业绩亏损额有所增加。 ...

Group 1 - The company Zhongnong United expects a net loss attributable to shareholders of 128 million to 165 million yuan for the year 2025, with basic earnings per share loss ranging from 0.9 to 1.16 yuan [1] - In the same period last year, the company reported a net loss of approximately 122 million yuan, with basic earnings per share loss of 0.86 yuan [1] - The primary reasons for the performance change include a sustained decline in market prices of the company's main products, leading to low gross margins, and high costs during the trial operation of newly completed projects, resulting in an increased loss for the reporting period [1]

Core Viewpoint - The company's stock experienced an abnormal fluctuation with a cumulative closing price deviation exceeding 20% over two consecutive trading days on January 23 and January 26, 2026 [1] Group 1: Stock Performance - The stock price deviation was identified as an abnormal fluctuation, prompting a review by the company [1] - The company confirmed that there were no undisclosed significant information affecting the stock price during the fluctuation period [1] Group 2: Company Operations - The company reported that its production and operational environment remains normal [1] - There were no undisclosed major matters by the company or its controlling shareholders during the abnormal fluctuation [1] Group 3: Financial Reporting - The company plans to disclose its 2025 annual report on April 29, 2026 [1]

证券日报网讯1月26日，利民股份（002734）在互动平台回答投资者提问时表示，截至2025年12月31 日，公司股东总户数为56060户。 ...

Group 1 - The company, Xinda Co., expects to achieve a net profit attributable to shareholders of between 135 million to 155 million yuan for the year 2025, marking a turnaround from a loss in the previous year [1] - In the previous year, the company reported a total profit loss of 42.87 million yuan, with a net loss attributable to shareholders of 25.88 million yuan and a net loss of 38.18 million yuan after excluding non-recurring gains and losses [1] - The main reason for the performance change is the significant increase in the sales price of the company's primary product, Acetochlor, which has boosted the overall gross margin of the company's products [1] Group 2 - The successful launch and sales of the newly developed product series, Pyrazole Acetochlor, have further contributed to the growth of the gross margin for domestic formulation products [1]

Group 1 - The company Hongyang announced that its 10th board meeting will be held on January 26, 2026, in Nanjing, discussing the proposal for issuing overseas bonds [1] Group 2 - International gold prices have surpassed $5,000, marking a 280% increase over the past seven years, with experts indicating that the key factors for future trends will depend on the US dollar, the international monetary system, interest rate cuts, and technological revolutions [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 135 million to 155 million yuan for the year 2025, marking a turnaround from losses in the previous year [1] Financial Performance - The projected net profit for 2025 represents a significant improvement compared to the previous year, indicating a recovery in financial performance [1] - The expected net profit after deducting non-recurring gains and losses is estimated to be between 120 million and 140 million yuan [1] Product and Market Dynamics - The sales price of the company's main product, Acetochlor, has significantly increased compared to the same period last year, contributing to an overall improvement in product gross margins [1] - The successful launch and sales of the newly developed product series, Pyrazole, have further driven the growth of gross margins for domestic formulation products [1] Operational Efficiency - The company is continuously advancing operational reforms and implementing a gross profit distribution plan, which enhances cost and expense management [1] - Overall operational efficiency is improving as a result of these initiatives [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 135 million to 155 million yuan for the year 2025, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The anticipated net profit represents a significant improvement compared to the previous year, indicating a successful recovery [1] - The sales price of the company's main product, Acetochlor, has significantly increased compared to the same period last year, contributing to the overall improvement in gross margin [1] Group 2: Product Development - The successful launch and sales of the newly developed product series, Pyrazole Quinclorac, have further boosted the gross margin of domestic formulation products [1] Group 3: Operational Efficiency - The company is continuously advancing operational reforms, implementing a gross profit distribution plan, and strengthening cost and expense control, leading to improved overall operational efficiency [1]

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 135 million to 155 million yuan for the year 2025, marking a turnaround from losses in the previous year [1] Financial Performance - The projected net profit for 2025 represents a significant improvement compared to the previous year, indicating a recovery in financial performance [1] - The expected net profit after deducting non-recurring gains and losses is estimated to be between 120 million and 140 million yuan [1] Product and Market Dynamics - The sales price of the company's main product, Acetochlor, has significantly increased compared to the same period last year, contributing to an overall improvement in product gross margins [1] - The successful launch and sales of the newly developed product series, Pyrazole, have further driven the growth of gross margins for domestic formulation products [1] Operational Efficiency - The company is continuously advancing operational reforms and implementing a gross profit distribution plan, which enhances cost and expense management [1] - Overall operational efficiency is improving as a result of these initiatives [1]

Group 1 - The pesticide industry is experiencing favorable policies that are accelerating the elimination of outdated production capacity, focusing on compliance and profitability recovery among leading companies [3][11] - A new policy effective from January 1, 2026, mandates "one certificate, one product," which will significantly reduce the number of market brands and enhance industry concentration, benefiting compliant enterprises with abundant registration resources [12][11] - The recent adjustment in export tax policies aims to address overcapacity and high-toxicity products, pushing the industry towards high-quality development centered on technology and branding [11][3] Group 2 - The North Exchange's chemical new materials sector saw an increase of 5.11% in the week of January 19-23, 2026, outperforming other sectors [24][25] - Key stocks in the chemical new materials sector, such as Meibang Technology and Tianli Composite, experienced significant weekly gains of 32.89% and 16.47%, respectively [32][34] - The overall market performance indicates a recovery trend, with the North Exchange 50 index closing at 1588.66 points, reflecting a weekly increase of 2.60% [24][27] Group 3 - Ying Tai Biological's net profit for 2025 is projected to be between -2.6 billion and -2.0 billion yuan, a significant improvement from -5.87 billion yuan in 2024, indicating a recovery in profitability [5][21] - Jilin Carbon Valley is expected to report a net profit of 1.80 to 2.20 billion yuan in 2025, representing a year-on-year growth of 92.81% to 135.66% [5][67] - The overall recovery in the pesticide sector is reflected in the net profit growth rates, which turned positive in the fourth quarter of 2024 and continued to improve in 2025 [20][23]